3/30 Taiwan BIO Weekly
2026-03-30 |
| Taiwan BIO Weekly |
| Taiwan's fight to end hepatitis C 29 March, 2026 In line with the WHO’s "Guidance for Country Validation of Viral Hepatitis Elimination and Path to Elimination," Taiwan has reached the Gold Tier programmatic targets under the WHO Path to Elimination (PTE) framework for hepatitis C. This progress has been driven by the government's political will and the systematic integration of hepatitis prevention, screening, diagnosis, and treatment into a universal health care system. More... |
| PharmaEssentia formalizes US$46M arrival to Puerto Rico 27 March, 2026 PharmaEssentia (TW: 6446), a Taiwan-founded biopharmaceutical company, has finalized a US$46 million investment to establish manufacturing operations in Puerto Rico, a little more than six weeks after announcing plans to enter the local market. The agreement was finalized during a ceremony attended by government and economic development officials. Puerto Rico officials said the project would make PharmaEssentia the first Taiwanese company to establish operations on the island and described it as the result of a joint effort by the Department of Economic Development and Commerce (DDEC, in Spanish) and Invest Puerto Rico. More... |
| Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 Press release 27 March, 2026 Jyong Biotech Ltd. (Nasdaq: MENS), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). More... |
| TTY Biopharm hits record revenue and profit in 2025, new drugs to drive growth this year 25 March, 2026 TTY Biopharm (TW: 4105) announced that it had achieved record-high revenue and profit in 2025, driven by a "three-arrow" strategy consisting of exports of difficult-to-manufacture generics such as Lipo-AB, in-licensed innovative drugs, and the development of domestically produced new drugs. This year, with the continued increase in market share of Lipo-AB and the addition of new drugs for blood cancers and lung cancer, operational growth momentum is expected to continue. In 2025, the company reported revenue of NT$6.45 billion, net profit attributable to the parent company of NT$1.56 billion, and earnings per share (EPS) of NT$6.27, each reaching record highs. More... (in Chinese) |
| Calgent Biotechnology opens new headquarters, targets IPO in 2027 25 March, 2026 Calgent Biotechnology announced on 25th March the official inauguration of its new operations and R&D headquarters in New Taipei City. Moving forward, the company will focus on translational medicine and cross-disciplinary integration to accelerate new drug development, targeting listing on Taiwan's Emerging Stock Market by the end of 2026 and advancing toward an IPO in 2027. Calgent Biotechnology focuses on three major therapeutic areas: oncology, immunology and inflammation, and metabolic diseases, with a pipeline spanning both small molecules and biologics, including nanobodies. More... (in Chinese) |
| HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering Press release 25 March, 2026 HanchorBio, Inc. (TW: 7827), a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures. More... |
| Taiwan's MedTech Ecosystem Attracts Global Interest Ahead of Medical Taiwan 2026 24 March, 2026 As healthcare systems worldwide accelerate digital transformation, international buyers and healthcare providers are increasingly seeking reliable partners capable of delivering innovative medical technologies, integrated digital solutions, and resilient supply chains. In recent years, Taiwan has emerged as an important hub for medical technology development and manufacturing in Asia. More... |
| Orient Pharma's rheumatoid arthritis drug to launch in the US, targets 20% market share 24 March, 2026 Orient Pharma (TW: 4166), part of the Orient EuroPharma Group, has continued to show strong operational performance. In a company announcement on 24th March stated that the company's core product, the long-acting oral extended-release rheumatoid arthritis drug Tofacitinib XR (11mg/22mg), is expected to launch in the US in June this year. Through sales efforts in partnership with Cipla, the drug is projected to capture 20–25% of the US market. More... (in Chinese) |
| AP Biosciences licenses IBI302 from Innovent Biologics, Phase III trial achieves primary endpoint 24 March, 2026 AP Biosciences (TW: 6945) announced on 24th March that it received notification from China's Innovent Biologics (Suzhou) that IBI302 has achieved the primary endpoint in its pivotal Phase III registration trial (STAR study). IBI302 is being developed for the treatment of neovascular age-related macular degeneration and diabetic retinopathy. More... (in Chinese) |
| U-Neuron Biomedical unveils i-ExoCraft platform, ushering in designer exosomes 23 March, 2026 U-Neuron Biomedical (TW: 6973), hosted a presentation on intelligent integrated exosome design and manufacturing, and next-generation regenerative medicine applications, noting that it had accumulated comprehensive patented technologies for the isolation and culture of amniotic fluid stem cells. Building on this foundation, the company has established a research and development platform to develop a diverse product portfolio spanning new drugs, medical aesthetics, and health supplements. More... (in Chinese) |
| GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC Press release 23 March, 2026 GlycoNex, Inc. (TW: 4168), a [Taiwan-based] clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Under the agreement, the two companies will jointly support preclinical development activities for GNX201-ADC, leveraging their respective expertise in antibody engineering and oncology drug development. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |